Marker Therapeutics (MRKR) Board & Incentive Changes
Marker Therapeutics announced material updates regarding governance and executive compensation on October 31, 2025.
New Director Appointment: The Board appointed Ms. Kathryn Penkus Corzo, effective November 1, 2025.
- Ms. Corzo brings deep industry experience from roles at Takeda, Sanofi, and currently as President/COO of bit.bio.
- She received a grant of 147,611 stock options, vesting over 36 months.
CEO Stock Award: CEO Dr. Juan Vera received a discretionary award of 250,000 stock options.